Last reviewed · How we verify
0.375% ROPIVACAINE
At a glance
| Generic name | 0.375% ROPIVACAINE |
|---|---|
| Also known as | Ropivacaine Hydrochloride Injection , Naropin , AstraZeneca AB, Sweden |
| Sponsor | Thomas Jefferson University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy (NA)
- Ultrasound-Guided Rhomboid-Intercostal Block Versus Thoracic Paravertebral Block for VATS Analgesia (NA)
- Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery (NA)
- External Oblique Intercostal Block Versus Erector Spinae Plane Block on Postoperative Pain in Laparoscopic Radical Gastrectomy (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- RISS Block for Enhanced Recovery After Video-Assisted Thoracoscopic Surgery (NA)
- Evaluating the Efficacy of the Psoas Sheath Block for Post Operative Analgesia Following Hip Arthroplasty (NA)
- Dexamethasone as ESPB Adjuvant in Lumbar Laminectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.375% ROPIVACAINE CI brief — competitive landscape report
- 0.375% ROPIVACAINE updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI